GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » Interest Coverage

Alphamab Oncology (STU:3NK) Interest Coverage : 0 (At Loss) (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Alphamab Oncology's Operating Income for the six months ended in Jun. 2024 was €-9.86 Mil. Alphamab Oncology's Interest Expense for the six months ended in Jun. 2024 was €-0.71 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Alphamab Oncology's Interest Coverage or its related term are showing as below:


STU:3NK's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 150.72
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Alphamab Oncology Interest Coverage Historical Data

The historical data trend for Alphamab Oncology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alphamab Oncology Interest Coverage Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - - -

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alphamab Oncology's Interest Coverage

For the Biotechnology subindustry, Alphamab Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alphamab Oncology's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alphamab Oncology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Alphamab Oncology's Interest Coverage falls into.



Alphamab Oncology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alphamab Oncology's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Alphamab Oncology's Interest Expense was €-1.56 Mil. Its Operating Income was €-39.24 Mil. And its Long-Term Debt & Capital Lease Obligation was €22.68 Mil.

Alphamab Oncology did not have earnings to cover the interest expense.

Alphamab Oncology's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Here, for the six months ended in Jun. 2024, Alphamab Oncology's Interest Expense was €-0.71 Mil. Its Operating Income was €-9.86 Mil. And its Long-Term Debt & Capital Lease Obligation was €19.53 Mil.

Alphamab Oncology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Alphamab Oncology  (STU:3NK) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Alphamab Oncology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Alphamab Oncology Business Description

Traded in Other Exchanges
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines